Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

CitiusTech's John Edward discusses how AI can transform healthcare despite imperfect data, exploring Agentic AI, data quality ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell ...

Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics ...

Five African countries, including Ethiopia, Malawi, Tanzania, Zambia, and Zimbabwe, have began treating patients with ...

The use of digital health technology (DHT) is increasing worldwide. Clinical trials assessing available health tools for the ...

The in-form attacker looked in bother when he hit the turf with nobody around him during Cork's final round league win over ...

Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient ...

Daniel Barber; President, Chief Executive Officer, Director; Aquestive Therapeutics Inc. Ernest Toth; Chief Financial ...